Back Home ADA 2005 Scientific Sessions

The CWD Quilt for Life was displayed at the 2005 ADA conference. Many people said that viewing the Quilt was the highlight of their time in San Diego. See the Quilt for Life Report for more photos.

The American Diabetes Association 2005 Scientific Sessions were held in San Diego, California from June 10-14, 2005 and offered an opportunity to learn about the latest in diabetes research, meet with researchers and clinicians, and meet with industry representatives. Children with Diabetes showed our Quilt for Life and had a small booth.

Research and Poster Presentations

  1. In Dilution of NovoLog® (insulin aspart 100 U/ml) with NPH medium for small dose use in continuous subcutaneous insulin infusion does not affect in-vitro stability, researchers from Novo Nordisk in Denmark reported excellent results using NovoLog diluted to 10 U/ml (1/10 strength) and 50 U/ml (1/2 strength) when used in insulin pumps for up to seven days. Diluting NovoLog can make it much easier for very young children to use insulin pumps. This poster also noted that pre-diluted NovoLog can be stored in sterile glass vials for up to one month at 5 degrees C (41 degrees F). If you're interested in diluting NovoLog, ask your pharmacist for the Novo Nordisk NPH diluent.

  2. In Mixing Rapid-acting Insulin Analogs with Insulin Glargine in Youth with Type 1 Diabetes, a team of researchers from the Barbara Davis Center in Denver reported on a six-month study of 55 kids with type 1 diabetes who mixed Lantus with a rapid acting analog (NovoLog or Humalog) and compared their blood sugar control with 55 kids who did not mix. Their data showed no significant differences in HbA1c; percentage of blood sugar readings in, above, or below a target range; nonsevere and severe hypoglycemia; or episodes of DKA. In summary, the ream concludes that mixing Lantus with a rapid acting analog had no effect on blood sugar control and doing so results in fewer daily injections, possibly offering kids an easier diabetes regimen.

  3. Computerized Automated Reminder Diabetes System (CARDS): Increasing Adherence to Diabetes Management Tasks Via the Web and SMS Text Messaging reported on a program that uses Web and SMS messaging to help teens with type 1 diabetes to check their blood sugars more often than they otherwise would.

  4. Medtronic Reports New Studies Confirming That Pump Therapy Improves Blood Sugar Control In Pediatric Diabetes Patients, a press release from Medtronic MiniMed, summarizes several abstracts related to pump use in children with diabetes.


  1. The Mixing of Rapid-Acting Insulin (RAI) Analogues (Humalog® or NovoLog®) with Insulin Glargine in Youth with Type 1 Diabetes (T1D) by Rosanna Fiallo-Scharer, Peter Chase, Brian Horner, Kim McFann, Philippe Walravens, and Satish Garg [1879-P]
    In this abstract, the team from the Barbara Davis Center in Denver, Colorado, found essentially no adverse effect from mixing either Humalog or NovoLog in the same syringe as Lantus in an effort to reduce the number of daily injections. This study followed 45 study and 45 control patients for six months prior to and three months after mixing.

  2. Assessment of Subclinical Atherosclerosis and Related Cardiovascular Disease (CVD) Risk Factors in Adolescents with Type 1 Diabetes (T1DM) by Maria V. Karantza, Simon R. Bababeygy, Howard N. Hodis, Wendy J. Mack, Chao-Ran Liu, Ci-Hua Liu, and Francine R. Kaufman [261-OR]
    In this abstract, the team from Children's Hospital Los Angeles measured the carotid artery intima-media thickness (IMT) in 90 young people with type 1 diabetes, ages 12-21, and 16 age-matched controls. They found that males, but not females, had a significantly higher IMT, showing evidence of early atherosclerosis.

  3. Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes (T1DM) by Eva Tsalikian, Roy Beck, H. Peter Chase, Tim Wysocki, Bruce Buckingham, Stuart Weinzimer, Nelly Mauras, Katrina Ruedy, Craig Killman, Dongyuan Xing, William Tamborlane, Diabetes Research in Children Network (DirecNet) Study Group [260-OR]
    The DirecNet team noted that "nocturnal hypoglycemia following aerobic exercise has been recognized clinically but not well studied." So this nationwide team took it upon themselves to conduct such a study. They studied 50 kids with type 1 diabetes and found a nearly five-fold increase in the risk of nocturnal hypoglycemia on days when a child exercised compared to days when they did not [26% of exercise nights vs. 6% of sedentary nights].

  4. The PedPump Study: A Low Percentage of Basal Insulin and More Than Five Daily Boluses Are Associated with Better Centralized HbA1c in 1041 Children on CSII from 17 Countries by Thomas Danne, Tadej Battelino, Przemyslawa Jaroszchobot, Olga Kordonouri, Eqa Pankowska, Moshe Phillip (The PedPump Study Group) [1887-P]
    The PedPump Study Group examined pump memories from 1,041 patients with type 1 diabetes and found that children who took five or more boluses per day had a significantly better HbA1c compared with children who took fewer boluses (7.8 +/- 1.1 vs. 8.7 +/- 1.6%).

Products and Product News

There was surprisingly little new in the way of diabetes products shown at the 2005 Scientific Sessions. Among the few newsworthy items were:

  1. Abbott Diabetes Care showed a new version of their FreeStyle meter, called the FreeStyle Freedom, which looks like a slightly enlarged FreeStyle Flash, but without the port light. The Freedom is not yet for sale in the United States. Abbott also showed a new glucose test strip for their Precision Xtra, which requires only 0.6 microliters of blood and yields results in five seconds.

  2. Roche Diagnostics showed their new Aviva blood glucose meter and Multiclix lancet device. These are not yet available in the United States.

  3. Dexcom had a booth to meet and talk with clinicians and researchers about their continuous glucose sensor, which is still under development. They had a poster, entitled A Randomized Controlled Study of a Transcutaneous, Real-Time Continous Glucose Sensor Demonstrates Improvement in Glycemic Control, that reported on a study of 91 patients with type 1 and type 2 diabetes who used the Dexcom sensor. The group who were able to see the real-time data experienced a significant improvement in control, spending 21% less time low (< 51 mg/dl), 23% less time high (> 240 mg/dl), and 26% more time in the target range (81-140 mg/dl). The control group did not see real time data or have low alarms, but if they had had alarms, the low alarm would have predicted 95% of the <= 55 mg/dl events.

More Information From ADA 2005

  Back Home Return to the Top of This Page

Last Updated: (none)
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.